Supernus Pharmaceuticals (SUPN) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.

Do analysts recommend JAZZ or SUPN?

Jazz Pharmaceuticals presently has a consensus price target of $177.00, indicating a potential upside of 46.06%. Supernus Pharmaceuticals has a consensus price target of $46.50, indicating a potential upside of 23.21%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87
Supernus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has higher valuation and earnings, JAZZ or SUPN?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$3.83B	1.91	$414.83M	$7.10	17.07
Supernus Pharmaceuticals	$651.97M	3.20	$1.32M	$1.07	35.27

Does the media favor JAZZ or SUPN?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Jazz Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.80 beat Jazz Pharmaceuticals' score of 0.97 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders & institutionals believe in JAZZ or SUPN?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community believe in JAZZ or SUPN?

Jazz Pharmaceuticals received 651 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. Likewise, 80.76% of users gave Jazz Pharmaceuticals an outperform vote while only 73.04% of users gave Supernus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Jazz Pharmaceuticals	Outperform Votes 1125 80.76%	Underperform Votes 268 19.24%
Supernus Pharmaceuticals	Outperform Votes 474 73.04%	Underperform Votes 175 26.96%

Which has more risk & volatility, JAZZ or SUPN?

Jazz Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

Is JAZZ or SUPN more profitable?

Jazz Pharmaceuticals has a net margin of 11.60% compared to Supernus Pharmaceuticals' net margin of 9.16%. Jazz Pharmaceuticals' return on equity of 29.30% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.60%	29.30%	9.72%
Supernus Pharmaceuticals	9.16%	7.79%	5.67%

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 13 of the 18 factors compared between the two stocks.